{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T16:58:47Z","timestamp":1780592327253,"version":"3.54.1"},"reference-count":23,"publisher":"Japanese Society of Internal Medicine","issue":"13","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2023,7,1]]},"DOI":"10.2169\/internalmedicine.0730-22","type":"journal-article","created":{"date-parts":[[2022,11,22]],"date-time":"2022-11-22T22:11:06Z","timestamp":1669155066000},"page":"1887-1893","source":"Crossref","is-referenced-by-count":17,"title":["Impact of the Extent of Weight Loss before Administration on the Efficacy of Anamorelin in Advanced Pancreatic Cancer Patients with Cachexia"],"prefix":"10.2169","volume":"62","author":[{"given":"Tsuyoshi","family":"Takeda","sequence":"first","affiliation":[{"name":"Department of Hepato-Biliary-Pancreatic Medicine, Cancer Institute Hospital of Japanese Foundation for Cancer Research, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Sasaki","sequence":"additional","affiliation":[{"name":"Department of Hepato-Biliary-Pancreatic Medicine, Cancer Institute Hospital of Japanese Foundation for Cancer Research, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeshi","family":"Okamoto","sequence":"additional","affiliation":[{"name":"Department of Hepato-Biliary-Pancreatic Medicine, Cancer Institute Hospital of Japanese Foundation for Cancer Research, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahiro","family":"Ishitsuka","sequence":"additional","affiliation":[{"name":"Department of Hepato-Biliary-Pancreatic Medicine, Cancer Institute Hospital of Japanese Foundation for Cancer Research, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manabu","family":"Yamada","sequence":"additional","affiliation":[{"name":"Department of Hepato-Biliary-Pancreatic Medicine, Cancer Institute Hospital of Japanese Foundation for Cancer Research, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroki","family":"Nakagawa","sequence":"additional","affiliation":[{"name":"Department of Hepato-Biliary-Pancreatic Medicine, Cancer Institute Hospital of Japanese Foundation for Cancer Research, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takafumi","family":"Mie","sequence":"additional","affiliation":[{"name":"Department of Hepato-Biliary-Pancreatic Medicine, Cancer Institute Hospital of Japanese Foundation for Cancer Research, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takaaki","family":"Furukawa","sequence":"additional","affiliation":[{"name":"Department of Hepato-Biliary-Pancreatic Medicine, Cancer Institute Hospital of Japanese Foundation for Cancer Research, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akiyoshi","family":"Kasuga","sequence":"additional","affiliation":[{"name":"Department of Hepato-Biliary-Pancreatic Medicine, Cancer Institute Hospital of Japanese Foundation for Cancer Research, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masato","family":"Matsuyama","sequence":"additional","affiliation":[{"name":"Department of Hepato-Biliary-Pancreatic Medicine, Cancer Institute Hospital of Japanese Foundation for Cancer Research, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masato","family":"Ozaka","sequence":"additional","affiliation":[{"name":"Department of Hepato-Biliary-Pancreatic Medicine, Cancer Institute Hospital of Japanese Foundation for Cancer Research, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoki","family":"Sasahira","sequence":"additional","affiliation":[{"name":"Department of Hepato-Biliary-Pancreatic Medicine, Cancer Institute Hospital of Japanese Foundation for Cancer Research, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Fearon K, Strasser F, Anker SD, et al. Definition and classification of cancer cachexia: an international consensus. Lancet Oncol 12: 489-495, 2011.","DOI":"10.1016\/S1470-2045(10)70218-7"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Martin L, Birdsell L, Macdonald N, et al. Cancer cachexia in the age of obesity: skeletal muscle depletion is a powerful prognostic factor, independent of body mass index. J Clin Oncol 31: 1539-1547, 2013.","DOI":"10.1200\/JCO.2012.45.2722"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. da Rocha IMG, Marcadenti A, de Medeiros GOC, et al. Is cachexia associated with chemotherapy toxicities in gastrointestinal cancer patients? A prospective study J Cachexia Sarcopenia Muscle 10: 445-454, 2019.","DOI":"10.1002\/jcsm.12391"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Takeda T, Sasaki T, Suzumori C, et al. The impact of cachexia and sarcopenia in elderly pancreatic cancer patients receiving palliative chemotherapy. Int J Clin Oncol 26: 1293-1303, 2021.","DOI":"10.1007\/s10147-021-01912-0"},{"key":"5","doi-asserted-by":"publisher","unstructured":"5. Ozola Zalite I, Zykus R, Francisco Gonzalez M, et al. Influence of cachexia and sarcopenia on survival in pancreatic ductal adenocarcinoma: a systematic review. Pancreatology 15: 19-24, 2015.","DOI":"10.1016\/j.pan.2014.11.006"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Baldwin C, Spiro A, McGough C, et al. Simple nutritional intervention in patients with advanced cancers of the gastrointestinal tract, non-small cell lung cancers or mesothelioma and weight loss receiving chemotherapy: a randomised controlled trial. J Hum Nutr Diet 24: 431-440, 2011.","DOI":"10.1111\/j.1365-277X.2011.01189.x"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Oldervoll LM, Loge JH, Lydersen S, et al. Physical exercise for cancer patients with advanced disease: a randomized controlled trial. Oncologist 16: 1649-1657, 2011.","DOI":"10.1634\/theoncologist.2011-0133"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Roeland EJ, Bohlke K, Baracos VE, et al. Management of cancer cachexia: ASCO guideline. J Clin Oncol 38: 2438-2453, 2020.","DOI":"10.1200\/JCO.20.00611"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Lim YL, Teoh SE, Yaow CYL, et al. A systematic review and meta-analysis of the clinical use of megestrol acetate for cancer-related anorexia\/cachexia. J Clin Med 11: 3756, 2022.","DOI":"10.3390\/jcm11133756"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Temel JS, Abernethy AP, Currow DC, et al. Anamorelin in patients with non-small-cell lung cancer and cachexia (ROMANA 1 and ROMANA 2): results from two randomised, double-blind, phase 3 trials. Lancet Oncol 17: 519-531, 2016.","DOI":"10.1016\/S1470-2045(15)00558-6"},{"key":"11","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1002\/cncr.31128","volume":"124","author":"N Katakami","year":"2018","unstructured":"11. Katakami N, Uchino J, Yokoyama T, et al. Anamorelin (ONO-7643) for the treatment of patients with non-small cell lung cancer and cachexia: results from a randomized, double-blind, placebo-controlled, multicenter study of Japanese patients (ONO-7643-04). Cancer 124: 606-616, 2018.","journal-title":"Cancer","ISSN":"https:\/\/id.crossref.org\/issn\/0008-543X","issn-type":"print"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Takayama K, Katakami N, Yokoyama T, et al. Anamorelin (ONO-7643) in Japanese patients with non-small cell lung cancer and cachexia: results of a randomized phase 2 trial. Support Care Cancer 24: 3495-3505, 2016.","DOI":"10.1007\/s00520-016-3144-z"},{"key":"13","doi-asserted-by":"publisher","unstructured":"13. Hamauchi S, Furuse J, Takano T, et al. A multicenter, open-label, single-arm study of anamorelin (ONO-7643) in advanced gastrointestinal cancer patients with cancer cachexia. Cancer 125: 4294-4302, 2019.","DOI":"10.1002\/cncr.32406"},{"key":"14","doi-asserted-by":"publisher","unstructured":"14. Naito T, Uchino J, Kojima T, et al. A multicenter, open-label, single-arm study of anamorelin (ONO-7643) in patients with cancer cachexia and low body mass index. Cancer 128: 2025-2035, 2022.","DOI":"10.1002\/cncr.34154"},{"key":"15","doi-asserted-by":"publisher","unstructured":"15. Kurihara M, Shimizu H, Tsuboi K, et al. Development of quality of life questionnaire in Japan: quality of life assessment of cancer patients receiving chemotherapy. Psycho-oncology 8: 355-363, 1999.","DOI":"10.1002\/(SICI)1099-1611(199907\/08)8:4<355::AID-PON401>3.0.CO;2-I"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Kanda Y. Investigation of the freely available easy-to-use software &apos;EZR&apos; for medical statistics. Bone Marrow transplant 48: 452-458, 2013.","DOI":"10.1038\/bmt.2012.244"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Currow D, Temel JS, Abernethy A, Milanowski J, Friend J, Fearon KC. ROMANA 3: a phase 3 safety extension study of anamorelin in advanced non-small-cell lung cancer (NSCLC) patients with cachexia. Ann Oncol 28: 1949-1956, 2017.","DOI":"10.1093\/annonc\/mdx192"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Khalid U, Spiro A, Baldwin C, et al. Symptoms and weight loss in patients with gastrointestinal and lung cancer at presentation. Support Care Cancer 15: 39-46, 2007.","DOI":"10.1007\/s00520-006-0091-0"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Aggarwal G, Kamada P, Chari ST. Prevalence of diabetes mellitus in pancreatic cancer compared to common cancers. Pancreas 42: 198-201, 2013.","DOI":"10.1097\/MPA.0b013e3182592c96"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Iglesia D, Avci B, Kiriukova M, et al. Pancreatic exocrine insufficiency and pancreatic enzyme replacement therapy in patients with advanced pancreatic cancer: a systematic review and meta-analysis. United Eur Gastroenterol J 8: 1115-1125, 2020.","DOI":"10.1177\/2050640620938987"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Yennurajalingam S, Basen-Engquist K, Reuben JM, et al. Anamorelin combined with physical activity, and nutritional counseling for cancer-related fatigue: a preliminary study. Support Care Cancer 30: 497-509, 2022.","DOI":"10.1007\/s00520-021-06463-8"},{"key":"22","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1186\/s12885-019-5762-6","volume":"19","author":"S Miura","year":"2019","unstructured":"22. Miura S, Naito T, Mitsunaga S, et al. A randomized phase II study of nutritional and exercise treatment for elderly patients with advanced non-small cell lung or pancreatic cancer: the NEXTAC-TWO study protocol. BMC cancer 19: 528, 2019.","journal-title":"BMC Cancer","ISSN":"https:\/\/id.crossref.org\/issn\/1471-2407","issn-type":"print"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Tobberup R, Carus A, Rasmussen HH, et al. Feasibility of a multimodal intervention on malnutrition in patients with lung cancer during primary anti-neoplastic treatment. Clin Nutr 40: 525-533, 2021.","DOI":"10.1016\/j.clnu.2020.05.050"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/62\/13\/62_0730-22\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T03:26:48Z","timestamp":1688182008000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/62\/13\/62_0730-22\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,1]]},"references-count":23,"journal-issue":{"issue":"13","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.0730-22","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,1]]},"article-number":"0730-22"}}